Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TQC3927 in Healthy Adults
NCT06408285Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing TQC3927 with Placebo (2 arms). Primary endpoints: Adverse events (AE), Serious adverse events (SAE) and 14 more. Started May 2024; status: completed.
02
Drugs
TQC3927
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06408285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408285.